Skip to content

In the BioHarmony Drug Report Database

Simoctocog alfa

Nuwiq, Vihuma (simoctocog alfa) is a protein pharmaceutical. Simoctocog alfa was first approved as Nuwiq on 2014-07-22. It is used to treat factor VII deficiency, hemophilia a, hemorrhage, and von willebrand diseases in the USA. It has been approved in Europe to treat hemophilia a.
Trade Name Nuwiq, Vihuma
Common Name Simoctocog alfa
Indication factor vii deficiency, hemophilia a, hemorrhage, von willebrand diseases
Drug Class
Simoctocog alfa
Get full access now